Genprex (GNPX) Reaches New 12-Month Low at $1.50

Genprex Inc (NASDAQ:GNPX) hit a new 52-week low during trading on Thursday . The stock traded as low as $1.50 and last traded at $1.54, with a volume of 150 shares trading hands. The stock had previously closed at $1.55.

Separately, Maxim Group initiated coverage on shares of Genprex in a research report on Friday, September 14th. They issued a “buy” rating and a $5.00 price target for the company.

TRADEMARK VIOLATION WARNING: This article was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at

About Genprex (NASDAQ:GNPX)

Genprex, Inc, a clinical stage gene therapy company, develops drugs to treat cancer. Its lead product candidate is Oncoprex, an active anti-cancer agent that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). It also conducts preclinical research for developing Oncoprex to be administered with immunotherapies in NSCLC; and research into other tumor suppressor genes associated with chromosome.

Featured Article: Closed-End Mutual Funds (CEFs)

Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with's FREE daily email newsletter.

Leave a Reply